Tianjin TEDA Biomedical Engineering Company Limited reported that its authorised and issued share capital remained unchanged throughout August 2026, according to the monthly return filed with Hong Kong Exchanges and Clearing on 2 September 2026.
Total authorised share capital stood at RMB 213.39 million, divided into: • 1.44 billion H shares with a par value of RMB 0.10 each; • 0.70 billion domestic shares with a par value of RMB 0.10 each.
Issued capital was also unchanged at 2.13 billion shares, comprising: • 1.44 billion H shares listed on GEM; • 0.70 billion unlisted domestic shares. No treasury shares were held, issued, or cancelled during the month.
The company confirmed full compliance with the GEM Listing Rule’s minimum 25% public-float requirement for its H-share class.
No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or outstanding, and there were no share repurchases, redemptions, or other capital movements during the period.
The return was duly authorised by Director Sun Li and submitted in accordance with Hong Kong listing regulations.